Continuous manufacturing offers QbD and PAT advantages says ISP

By Gareth Macdonald

- Last updated on GMT

Continuous manufacturing offers significant advantages for drug production in terms of quality and efficiency, but more research and regulatory input is needed to help the pharmaceutical sector reap the benefits according to ISP.

in-PharmaTechnologist spoke with Stuart Porter from excipients and coatings firm International Specialty Products (ISP) who will participate in a panel discussion of continuous manufacturing at ExcipientFest Americas next month.

Porter said that while individual continuous processes such as tabletting and dry granulation are well established in the drug sector the growing trend is for producers to tie these together which poses new challenges.

Batch

One of the main potential hurdles, according to Porter, is the need to find new ways of defining a batch that are not reliant on a finite quantity of material weighed out and recorded on a batch record.

Now rather than a quantity of materials used, a batch has to be thought of as a moment in time, whether it’s a 12or 24-four process​.”

He also suggested that the characteristics of raw materials fed into continuous process may have to be altered to improve, for example, the accuracy with which they are introduced.

Regulatory role

He also said that regulatory guidance would be helpful and suggested that organisations like the US Food and Drug Administration (FDA) would support the principal of continuous manufacturing from a quality perspective

I think they [the FDA] will embrace it because it fits with the whole concept of quality-by-design and PAT [process analytical technology]. A continuous process enables PAT initiatives… to be implemented more easily than some more conventional processes​.”

Porter's suggestion fits with comments made by FDA compliance officer Francis Godwin during a presentation at Interphex 2011 in New York earlier this month.

Related news

Show more

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

BioContinuum™ Platform - MilliporeSigma | 01-Jul-2020 | Technical / White Paper

Adoption of next generation processing and technologies can enable improvements in productivity by streamlining workflows, reducing the manufacturing plant...

Bio4C™ ProcessPad Software Datasheet

Bio4C™ ProcessPad Software Datasheet

BioContinuum™ Platform - MilliporeSigma | 01-Jul-2020 | Data Sheet

Biopharmaceutical processes are complex and highly variable in nature. This can result in inconsistent and sometimes unpredictable process outcomes. To...

Related suppliers

Follow us

Products

View more

Webinars